Vitamin K2 Market

The vitamin K2 market is estimated to be USD 140 million in 2024 and poised to achieve a 13.7% CAGR, reaching USD 265 million by 2029. As people become more informed about the role of vitamins in preventing chronic diseases, there is a heightened demand for Vitamin K2 due to its critical function in bone and cardiovascular health. Awareness campaigns and educational programs significantly contribute to this trend, emphasizing the benefits of Vitamin K2 in maintaining calcium balance and reducing the risk of osteoporosis and arterial calcification.

The global demographic shift towards an aging population is another significant factor propelling the Vitamin K2 market. Older adults are more susceptible to bone density loss and cardiovascular diseases, conditions that Vitamin K2 helps mitigate. As life expectancy increases, so does the need for nutritional supplements that support healthy aging. Consequently, the market for Vitamin K2 is experiencing substantial growth as it becomes an integral component of the dietary regimen for the elderly.

To know about the assumptions considered for the study download the pdf brochure

Gnosis by Lesaffre (NattoPharma) (France)

Gnosis, a business unit of Lesaffre, has leveraged nearly 170 years of fermentation expertise to become a leader in the field. Founded in 2018 through the merger of Gnosis Advanced Biotech and Lesaffre Human Care, and further expanded with the acquisition of NattoPharma in 2021, Gnosis focuses on producing fermentation-derived ingredients for dietary supplements, pharmaceuticals, and functional foods. The company operates in five key areas: immune health, digestive health, mobility and joint health, reproductive and women's health, and cognitive health. Lesaffre, with a diverse workforce of 11,000 employees across 96 nationalities, ensures quality and innovation through its global network of 63 application centers and state-of-the-art R&D facilities like the Fermentis Campus. The company is certified in ISO22000, Non-GMO, Halal, and Kosher.

In October 2022, Gnosis by Lesaffre has recently launched MenaQ7 Matrix at SupplySide West, strengthening its position as the leading supplier of Vitamin K2 as MK-7. MenaQ7 Matrix combines the premier MenaQ7 Vitamin K2 as MK-7 with the award-winning Matrix K2 enhanced protective technology. This proprietary technology protects menaquinone particles without the need for coatings, additives, or additional ingredients, addressing the complex stability issues related to moisture and mineral salts that often affect Vitamin K2 formulations.

Kappa Bioscience AS (Balchem Corp.) (US)

Since 2022, Kappa Bioscience has been part of Balchem Corporation, a US-based global leader in specialty ingredients focused on nutrition and health. Balchem, a public company, operates in human and animal nutrition and health. With a strong presence in over 70 countries and major subsidiaries like Albion International and SensoryEffects Inc., Balchem serves the food, beverage, pharmaceutical, and dietary supplement industries. Kappa Bioscience, a leading vitamin K2 producer from Norway, is part of Balchem's human nutrition and health segment. It has a geographical presence in over 70 countries across six continents.

In March 2022, Kappa Bioscience established a "Blue Ribbon" Scientific and Medical Advisory Board composed of prominent scientists from various fields. The advisory board aims to deepen and expand the scientific understanding of Menaquinone 7 (MK-7) Vitamin K2 and its associated health benefits.

J-OIL MILLS INC. (Japan)

J-OIL MILLS INC., headquartered in Japan, specializes in manufacturing and selling edible oils and fats, operating through its oils & fats and specialty food products segments. It also offers services like real estate leasing. The company addresses health, food safety, animal health, and environmental sustainability needs. Known for its expertise in Ajinomoto production, it has subsidiaries in Malaysia and Thailand. J-OIL Mills produces Vitamin K2, marketed in North America by PLT Health Solutions under the "Menatto" brand. Developed in 1997, Menatto has been researched in ten human clinical trials. PLT Health Solutions, with over 70 years of experience, has been in the Vitamin K2 business for nearly twenty years.

In March 2023, PLT Health Solutions, Inc. announced a partnership with J-OIL MLLS INC. to market the menatto brand of Vitamin K2 (MK-7) in North America. This premium-quality ingredient, developed by J-Oil Mills in 1997, utilizes fermentation technology with Bacillus subtilis isolated from the traditional Japanese food natto. Since its inception, menatto has been the subject of ten human clinical trials, including research on bioavailability, bone health, and cardiovascular health.

Related Reports:

Vitamin K2 Market by Product Type (MK-4, MK-7), Source (Natural, Synthetic), Form (Capsules & Tablets, Powder & Crystalline, Oils & Liquid), Application (Pharmaceutical, Functional Food & Beverages, Health Supplements), Function - Global Forecast to 2029

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]